Shots:Hengrui Pharma & Braveheart Bio have entered into an exclusive license agreement for Hengrui’s HRS-1893 to treat cardiovascular diseasesAs per the deal, Braveheart will obtain exclusive global rights (ex-China, Hong Kong, Macao & Taiwan) to develop, manufacture & commercialize HRS-1893 in exchange for $65M upfront (50% in cash + 50% in shares), ~$10M…
Shots:Eli Lilly has entered into a definitive agreement to acquire Verve Therapeutics to advance cardiovascular therapiesAs per the deal, Lilly will acquire Verve for $10.50/share in an all-cash transaction totaling ~$1B, along with one non-tradeable CVR of $3/share tied to first pts dosing with VERVE-102 for ASCVD in P-III trial by year 10 post-closing;…
Shots:Boston Scientific has agreed to acquire Bolt Medical, strengthening its cardiovascular portfolio with the addition of Bolt IVL system for coronary & peripheral disease. Deal is expected to close in H1’25
Boston, an investor with a 26% equity stake in Bolt Medical, is acquiring the rest 74% for $443M upfront & up to…
Environmental health is a crucial aspect of public welfare that encompasses the interactions between people and their environment. It focuses on the physical, chemical, and biological factors that impact human health and seeks to prevent and control environmental hazards that can lead to disease or injury. The importance of environmental health cannot be overstated as…

